WFM
ALXN

Wilmington Funds Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Wilmington Funds Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$1.01M Buy
6,440
+2,400
+59% +$379K 0.1% 204
2014
Q1 		$615K Hold
4,040
– – 0.07% 296
2013
Q4 		$538K Sell
4,040
-1,500
-27% -$180K 0.05% 371
2013
Q3 		$644K Hold
5,540
– – 0.06% 313
2013
Q2 		$511K Buy
+5,540
New +$534K 0.05% 366

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wilmington Funds Management's ALXN Position: Q2 2014 in Review

Wilmington Funds Management increased its Alexion Pharmaceuticals (ALXN) stake by 59% in Q2 2014, buying an estimated $379K and bringing the position to 6,440 shares worth $1.01M. The position accounts for 0.1% of the portfolio, ranked #204.

Wilmington Funds Management first reported a position in ALXN in Q2 2013 and has held it in 5 quarters since. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Wilmington Funds Management held 6,440 shares of Alexion Pharmaceuticals worth $1.01M as of Q2 2014.
  • Wilmington Funds Management bought 2,400 Alexion Pharmaceuticals shares in Q2 2014, an estimated $379K.
  • Alexion Pharmaceuticals made up 0.1% of Wilmington Funds Management's portfolio in Q2 2014, its #204 holding.
  • Wilmington Funds Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.